OBRIEN-TOPOTECAN-2006

Regimen

Experimental
oral topotecan 2.3 mg/m^2/d days 1-5 q21d + best supportive care
Control
best supportive care alone

Population

Relapsed small-cell lung cancer not candidates for standard IV therapy

Key finding

Median OS 25.9 vs 13.9 weeks (log-rank P=0.0104); ORR 7% PR + 44% SD; grade 4 neutropenia 33% on topotecan

Source: PMID 17135646

Timeline

    Guideline citations

    • NCCN SCLC (p.80)